Novo Ventures company plans to fetch USD 127.5m on the US stock exchange
The newly founded spinout company Vectivbio, which Novo Ventures has invested millions of kroner in, has announced that it is getting listed in the US with the goal of fetching USD 127.5m for developing a treatment for short bowel syndrome, which Zealand Pharma is also banking on.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
The battle for the short bowel syndrome market is getting tougher.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma will soon launch first drug
For subscribers
.jpg&w=384&q=75)
